These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 28276537)
1. Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease. Singal M; Kouides PA Drugs Today (Barc); 2016 Dec; 52(12):653-664. PubMed ID: 28276537 [TBL] [Abstract][Full Text] [Related]
2. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Franchini M; Mannucci PM Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955 [TBL] [Abstract][Full Text] [Related]
3. An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease. Hancock JM; Escobar MA Expert Rev Hematol; 2023 Mar; 16(3):157-161. PubMed ID: 36861346 [TBL] [Abstract][Full Text] [Related]
4. [Advances in the therapy for von Willebrand disease]. Nakayama T Rinsho Ketsueki; 2023; 64(5):389-396. PubMed ID: 37271530 [TBL] [Abstract][Full Text] [Related]
5. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Mannucci PM; Kempton C; Millar C; Romond E; Shapiro A; Birschmann I; Ragni MV; Gill JC; Yee TT; Klamroth R; Wong WY; Chapman M; Engl W; Turecek PL; Suiter TM; Ewenstein BM; Blood; 2013 Aug; 122(5):648-57. PubMed ID: 23777763 [TBL] [Abstract][Full Text] [Related]
7. Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience. Tran T; Arnall J; Moore DC; Ward L; Palkimas S; Man L J Thromb Thrombolysis; 2020 Apr; 49(3):431-440. PubMed ID: 31902122 [TBL] [Abstract][Full Text] [Related]
8. A personalized approach to the management of VWD. Phua CW; Berntorp E Transfus Apher Sci; 2019 Oct; 58(5):590-595. PubMed ID: 31466808 [TBL] [Abstract][Full Text] [Related]
9. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3. Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574 [TBL] [Abstract][Full Text] [Related]
10. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings. Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363 [TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL Wien Klin Wochenschr; 1999 Mar; 111(5):181-91. PubMed ID: 10226348 [TBL] [Abstract][Full Text] [Related]
12. Prophylaxis in von Willebrand disease. Franchini M; Targher G; Lippi G Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944 [TBL] [Abstract][Full Text] [Related]
13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
14. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. Peyvandi F; Mamaev A; Wang JD; Stasyshyn O; Timofeeva M; Curry N; Cid AR; Yee TT; Kavakli K; Castaman G; Sytkowski A J Thromb Haemost; 2019 Jan; 17(1):52-62. PubMed ID: 30362288 [TBL] [Abstract][Full Text] [Related]
15. Monitoring Therapy during Treatment of von Willebrand Disease. Favaloro EJ; Pasalic L; Curnow J Semin Thromb Hemost; 2017 Apr; 43(3):338-354. PubMed ID: 27472426 [TBL] [Abstract][Full Text] [Related]
16. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study. Federici AB Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy. Vinayagam S; Simons LR; Chowdary P; Thurlow P; Brooks SV; Riddell AF Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424 [TBL] [Abstract][Full Text] [Related]
18. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Berntorp E; Windyga J; Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848 [TBL] [Abstract][Full Text] [Related]
19. Mild forms of von Willebrand disease: diagnosis and management. Federici AB Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308 [TBL] [Abstract][Full Text] [Related]
20. Diagnosis and management of von Willebrand disease in Australia. Favaloro EJ; Bonar R; Favaloro J; Koutts J Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]